{
    "nct_id": "NCT06525298",
    "official_title": "A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors",
    "inclusion_criteria": "* Recurrent locally advanced or metastatic solid tumors\n* Homologous recombination deficient mutations\n* Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy\n* Measurable disease (RECIST 1.1 Criteria)\n* Adequate organ and bone marrow function\n* ECOG Performance Status 0 or 1\n* Life expectancy > 3 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History or evidence of any clinically relevant gastrointestinal disease\n* Radiation therapy within â‰¤2 weeks\n* Significant cardiovascular disease\n* Uncontrolled, active, symptomatic brain metastases",
    "miscellaneous_criteria": ""
}